Hodgkin Disease

  • M. K. Gospodarowicz
  • L. Specht
  • S. B. Sutcliffe
Part of the UICC International Union Against Cancer / Union Internationale Contre le Cancer book series (UICCI)


Improvements in patient assessment and treatment of Hodgkin disease allow us now to cure the majority of patients with this disease. These improved results have minimised the impact of prognostic factors and, currently, prognostic factors are employed more frequently to select therapy than to estimate survival. Over the last three decades, numerous factors have been shown to affect the prognosis of patients with Hodgkin disease. Most of these factors are highly interrelated. Consequently, multivariate analyses are needed to determine which factors are merely related to better known prognostic factors, but are without independent prognostic significance. A large number of multivariate studies of prognostic factors in Hodgkin disease have been published. The differing conclusions may be attributed to variation with regard to factors being examined, patient assessment and treatment, and the methods of analysis employed in individual studies. A comprehensive review of the literature on prognostic factors in Hodgkin disease emphasised both the wealth of data and differences in opinion due to the differences in recording and analysis of prognostic factors [35].


Prognostic Factor Combine Modality Therapy Hodgkin Disease Mixed Cellularity Independent Prognostic Significance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson H, Deakin DP, Wagstaff J Et Al (1984) A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin’s disease PS IA-III: a report from the Manchester Lymphoma Group. Br J Cancer 49: 695–702PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson H, Jenkins JPR, Brigg DJ Et Al (1985) The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin’s disease: a report from the Manchester Lymphoma Group. Clin Radiol 36: 449–454PubMedCrossRefGoogle Scholar
  3. 3.
    Bennett KH, MacLennan KA, Easterling MJ Et Al (1985) The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin’s disease: an analysis of 271 non-laparotomised cases (BNLI report no 22). Clin Radiol 34: 497–501CrossRefGoogle Scholar
  4. 4.
    Bonadonna G, Valagussa P, Santoro A (1985) Prognosis of bulky Hodgkin’s disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv 4: 439–458PubMedGoogle Scholar
  5. 5.
    Carbone PP, Kaplan HS, Musshoff K Et Al (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31: 1860–1861PubMedGoogle Scholar
  6. 6.
    Crnkovich MJ, Leopold K, Hoppe RT (1987) Stage I to IIB Hodgkin’s disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 5: 1041–1049PubMedGoogle Scholar
  7. 7.
    Davis S, Dahlberg S, Myers MH Et Al (1987) Hodgkin’s disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance, Epidemiology and End Results Program. J Natl Cancer Inst 78: 471–478PubMedGoogle Scholar
  8. 8.
    De Vita VT, Simon RM, Hubbard SM Et Al (1980) Curability of advanced Hodgkin’s disease with chemotherapy. Ann Intern Med 92: 587–594PubMedGoogle Scholar
  9. 9.
    Ferry JA, Linggood RM, Convery KM Et Al (1993) Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer 71: 457–463PubMedCrossRefGoogle Scholar
  10. 10.
    Fuller LM, Gamble JF, Schullenberger CC Et Al (1971) Prognostic factors in localized Hodgkin’s disease treated with regional radiation. Clinical presentation and specific histology. Radiology 98: 641–654PubMedGoogle Scholar
  11. 11.
    Gobbi PG, Cavalli C, Federico M Et Al (1988) Hodgkin’s disease prognosis: a directly predictive equation. Lancet I: 675–679Google Scholar
  12. 12.
    Golomb HM, Sweet DL, Ultmann JE Et Al (1980) Importance of substaging of stage III Hodgkin’s disease. Semin Oncol 7: 136–143PubMedGoogle Scholar
  13. 13.
    Gospodarowicz MK, Sutcliffe SB, Clark RM Et Al (1992) Analysis of supradiaphragmatic clinical stage I and II Hodgkin’s disease treated with radiation alone. Int J Radiat Oncol Biol Phys 22: 859–865PubMedCrossRefGoogle Scholar
  14. 14.
    Haybittle JL, Haygoe FGJ, Easterling M J Et Al (1985) Review of British National Lymphoma Investigation studies of Hodgkin’s disease and development of prognostic index. Lancet I: 967–972Google Scholar
  15. 15.
    Henry-Amar M, Aeppli DM, Anderson J Et Al (1990) Workshop statistical report. In: Somers R, Henry-Amar M, Meerwaldt JK Et Al (eds) Treatment strategy in Hodgkin’s disease. INSERM/ John Libbey Eurotext, London, pp 169–422Google Scholar
  16. 16.
    Hermanek P, Sobin LH (eds) (1992) UICC TNM classification of malignant tumours, 4th edn, 2nd rev. Springer, Berlin Heidelberg New YorkGoogle Scholar
  17. 17.
    Hoppe RT, Coleman CN, Cox RS Et Al (1982) The management of stage Ï-II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59: 455–465PubMedGoogle Scholar
  18. 18.
    Hoppe RT, Cox RS, Rosenberg SA Et Al (1982) Prognostic factors in pathologic stage III Hodgkin’s disease. Cancer Treat Rep 66: 743–749PubMedGoogle Scholar
  19. 19.
    Jafîe HS, Cadman EC, Farber LR Et Al (1986) Pretreatment hematocrit as an independent prognostic variable in Hodgkin’s disease. Blood 68: 562–564Google Scholar
  20. 20.
    Kaplan HS (1980) Hodgkin’s disease, 2nd edn. Harvard University Press, CambridgeGoogle Scholar
  21. 21.
    Liew KH, Easton D, Horwich A Et Al (1984) Bulky mediastinal Hodgkin’s disease management and prognosis. Hematol Oncol 2: 45–59PubMedGoogle Scholar
  22. 22.
    Loffler M, Dixon DO, Swindell R (1990) Prognostic factors of stage III and IV Hodgkin’s disease. In: Somers R, Henry-Amar M, Meerwaldt JK Et Al (eds) Treatment strategy in Hodgkin’s disease. John Libbey Eurotext, Paris, pp 90–103Google Scholar
  23. 23.
    Longo DL, Young RC, Wesley M (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4: 1295–1306PubMedGoogle Scholar
  24. 24.
    Lukes RJ, Craver LF, Hall TC Et Al (1966) Report of the Nomenclature Committee. Cancer Res 26: 1311Google Scholar
  25. 25.
    MacLennan KA, Bennett MH, Bosq J Et Al (1990) The histology and immunohistology of Hodgkin’s disease: its relationship to prognosis and clinical behaviour. In: Somers R, Henry- Amar M, Meerwaldt JK Et Al (eds) Treatment strategy in Hodgkin’s disease. John Libbey Eurotext, Paris, pp 17–25Google Scholar
  26. 26.
    Masih AS, Weisenburger DD, Vose JM Et Al (1992) Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin’s disease. Cancer 69: 228–232PubMedCrossRefGoogle Scholar
  27. 27.
    Mauch P, Goffman T, Rosenthal DS Et Al (1985) Stage III Hodgkin’s disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol 3: 1166–1173PubMedGoogle Scholar
  28. 28.
    Meerwaldt JH, Van Glabbeke M, Vaughan Hudson B (1990) Prognostic factors for stage I and II Hodgkin’s disease. In: Somers R, Henry-Amar M, Meerwaldt JK Et Al (eds) Treatment strategy in Hodgkin’s disease. John Libbey Eurotext, Paris, pp 37–50Google Scholar
  29. 29.
    Pavlovsky S, Maschio M, Santarelli MT Et Al (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease. J Natl Cancer Inst 80: 1466–1473PubMedCrossRefGoogle Scholar
  30. 30.
    Peters MV (1950) A study of survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol 63: 299–311Google Scholar
  31. 31.
    Peters MV, Middlemiss KCH (1958) A study of Hodgkin’s disease treated by irradiation. Am J Roentgenol 79: 114–121Google Scholar
  32. 32.
    Pillai AN, Hagemeister FB, Velasquez WS (1985) Prognostic factors for stage IV Hodgkin’s disease treated with MOPP, with or without bleomycin. Cancer 55: 691–697PubMedCrossRefGoogle Scholar
  33. 33.
    Prosnitz LR, Farber LR, Kapp DS Et Al (1982) Combined modality therapy for advanced Hodgkin’s disease: long-term follow-up data. Cancer Treat Rep 66: 871–879PubMedGoogle Scholar
  34. 34.
    Selby P, Patel P, Milan S Et Al (1990) ChlVPP combination chemotherapy for Hodgkin’s disease: long term results. Br J Cancer 62: 279–285PubMedCrossRefGoogle Scholar
  35. 35.
    Specht L (1991) Prognostic factors in Hodgkin’s disease. Cancer Treat Rev 18: 21–53PubMedCrossRefGoogle Scholar
  36. 36.
    Specht L (1992) Tumour burden as the main indicator of prognosis in Hodgkin’s disease. Eur J Cancer 28A: 1982–1985CrossRefGoogle Scholar
  37. 37.
    Specht L, Lauritzen AF, Nordentoft AM Et Al (1990) Tumour cell concentration and tumour burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin’s disease. Cancer 65: 2594–2601PubMedCrossRefGoogle Scholar
  38. 38.
    Specht L, Nissen NI (1988) Prognostic factors in Hodgkin’s disease stage IV. Eur J Hematol 41: 359–367CrossRefGoogle Scholar
  39. 39.
    Specht L, Nissen NI (1988) Prognostic factors in Hodgkin’s disease stage III with special reference to tumour burden. Eur J Hematol 41: 80–87CrossRefGoogle Scholar
  40. 40.
    Specht L, Nissen NI (1989) Hodgkin’s disease and age. Eur J Hematol 43: 127–135CrossRefGoogle Scholar
  41. 41.
    Specht L, Nordentoft AM, Soren S Et Al (1988) Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Cancer 61: 1719–1727PubMedCrossRefGoogle Scholar
  42. 42.
    Straus DJ, Gaynor JJ, Myers J Et Al (1990) Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8: 1173–1186PubMedGoogle Scholar
  43. 43.
    Sutcliffe SB, Gospodarowicz MK, Bergsagel DE Et Al (1985) Prognostic groups for management for localized Hodgkin’s disease. J Clin Oncol 3: 393–401PubMedGoogle Scholar
  44. 44.
    Sutcliffe SB, Wrigley PFM, Peto J Et Al (1978) MVPP chemotherapy regimen for advanced Hodgkin’s disease. Br Med J 1: 679–683PubMedCrossRefGoogle Scholar
  45. 45.
    Tubiana M, Henry-Amar M, Burgers MV Et Al (1984) Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin’s disease. J Clin Oncol 2: 194–200PubMedGoogle Scholar
  46. 46.
    Tubiana M, Henry-Amar M, Carde P Et Al (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood 73: 47–56PubMedGoogle Scholar
  47. 47.
    Tubiana M, Henry-Amar M, Hayat M Et Al (1984) Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer 54: 885–894PubMedCrossRefGoogle Scholar
  48. 48.
    Tubiana M, Henry-Amar M, Van der Werf-Messing B Et Al (1985) A multivariate analysis of prognostic factors in early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11: 23–30PubMedCrossRefGoogle Scholar
  49. 49.
    Verger E, Easton D, Brada M Et Al (1988) Radiotherapy results in laparotomy staged Hodgkin’s disease. Clin Oncol 39: 428–431.Google Scholar
  50. 50.
    Wagstaff J, Gregory WM, Swindell R Et Al (1988) Prognostic factors for survival in stage IIIB and IV Hodgkin’s disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer 58: 487–492PubMedCrossRefGoogle Scholar

Copyright information

© International Union Against Cancer, Geneva 1995

Authors and Affiliations

  • M. K. Gospodarowicz
  • L. Specht
  • S. B. Sutcliffe

There are no affiliations available

Personalised recommendations